IN THE CLAIMS

1. (Cancelled) ~~A method of treating a patient suffering from neuropathy which comprises treating said patient with an effective amount of a cGMP PDE5 inhibitor, with the proviso that the inhibitor is not a:~~

~~i) substituted 5-(3-pyridyl)pyrazolo[4,3-d]pyrimidin-7-one,~~

~~ii) substituted 2-(3-pyridyl)-4a,5-dihydroimidazo[5,1-*f*][1,2,4]triazin-4(3*H*)-one, or~~

~~iii) substituted 2-phenylpurin-6-one or a substituted 2-(3-pyridyl)purin-6-one,~~

~~for treating peripheral diabetic neuropathy.~~

2. (Cancel)
3. (Cancel)
4. (Cancel)
5. (Cancel)
6. (Cancel)
7. (Cancel)
8. (Cancel)
9. (Cancel)
10. (Cancel)
11. (Cancel)
12. (Cancel)
13. (Cancel)
14. (Cancel)
15. (Cancel)
16. (Cancel)

17. (Previously Presented) A combination comprising a therapeutically effective amount of a cGMP PDE5 inhibitor and a therapeutically effective amount of pregabalin or gabapentin.

18. (Previously Presented) A pharmaceutical composition comprising:

a therapeutically effective amount of a first compound said compound being a cGMP PDE5 inhibitor;

a therapeutically effective amount of a second compound said second compound being pregabalin or gabapentin; and

a pharmaceutically acceptable excipient, diluent or carrier.

19. (Previously Presented) The pharmaceutical composition as recited in claim 18 wherein the inhibitor has an IC50 at less than 100 nanomolar.

20. (Previously Presented) The pharmaceutical composition as recited in claim 19 wherein the inhibitor has a selectivity ratio in excess of 100.

21. (Previously Presented) The pharmaceutical composition as recited in claim 18 wherein the inhibitor is sildenafil, or pharmaceutically acceptable salts thereof.

22. (Previously Presented) The pharmaceutical composition as recited in claim 18 wherein said second compound comprises a therapeutically effective amount of pregabalin.

23. (Previously Presented) The pharmaceutical composition as recited in claim 18 wherein said second compound comprises a therapeutically effective amount of gabapentin.

24. (Previously Presented) The pharmaceutical composition as recited in claim 22 or 23 wherein the inhibitor has an IC50 at less than 100 nanomolar.

25. (Previously Presented) The pharmaceutical composition as recited in claim 22 or 23 wherein the inhibitor has a selectivity ratio in excess of 100.

26. (Previously Presented) The pharmaceutical composition as recited in claim 22 or 23 wherein the inhibitor is sildenafil, or pharmaceutically acceptable salts thereof.

27. (Currently Amended) A method of treating neuropathy in a patient suffering ~~from neuropathy~~ therefrom which comprises administering a patient in need of therapy thereof a therapeutically effective amount of a combination of a cGMP PDE5 inhibitor and pregabalin or gabapentin.

28. (Previously Presented) A method as recited in claim 27 wherein the neuropathy is diabetic polyneuropathy.

29. (Previously Presented) A method as recited in claim 27 or 28 wherein the inhibitor is administered orally

30. (Previously Presented) A method as recited to claim 29 wherein the inhibitor has an IC50 at less than 100 nanomolar.

31. (Previously Presented) A method as recited in claim 29 wherein the inhibitor has a selectivity ratio in excess of 100.

32. (Previously Presented) A method as recited in claim 29 wherein the inhibitor is sildenafil, or pharmaceutically acceptable salts thereof.

33. (Previously Presented) A method according to claim 29 wherein pregabalin is administered.

34. (Previously Presented) A method according to claim 29 wherein gabapentin is administered.